This week, Eko Health received FDA clearance for a new AI-powered tool that aids in the early detection of low ejection fraction, a key indicator of heart failure. The tool, which was developed in collaboration with Mayo Clinic, is embedded into Eko’s digital stethoscopes.
Eko recently launched an AI-powered software that its CEO describes as "Shazam for heartbeats." The platform connects with Eko's digital stethoscopes and identifies whether or not a patient's heart sounds are indicative of disease.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The Eko App uses automated disease detection software and is paired with the company's line of smart stethoscopes to analyze heart sounds with FDA-cleared AI algorithms. The redesigned app includes a range of new features to analyze heart sounds and cardiac rhythm for potential problems, the company said.
The company, which makes a digital stethoscope and electrocardiogram, raised $65 million in series C funding. It plans to use the funds to build out a telehealth platform and at-home monitoring program for cardiopulmonary patients.
The algorithm is not designed to replace consumer-facing devices. But while most smart watches track electrical signals from the heart, Eko focuses on sound as a means to improve the work of front-line clinicians.
The tool harnesses Mayo Clinic's cardiovascular database and expertise in heart disease screening combined with Eko's cardiac monitoring platform.
ARTIS Ventures led the Series A round. Other investors that took part included Strategic Partners, Dreamlt Ventures, 1812 Ventures, and FOUNDER.org.
The device can be used in a doctor's office and could be prescribed to heart disease patients to support remote monitoring and reduce readmissions.
Medical device company Eko got the greenlight from the FDA for its digital stethoscope Eko CORE.
